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Screening methods that use traditional genomic 1, 2, 3, transcriptional 4, proteomic 5, 6, and 
metabonomic7 signatures to characterise drug mechanisms exist. However, they are time-
consuming and require specialised equipment. Here, we present a high-throughput multi-
channel sensor platform that can profile the mechanisms of various chemotherapeutic drugs 
in minutes. The sensor consists of a gold nanoparticle (AuNP) complexed with three 
different fluorescent proteins (FPs) that can sense drug-induced physicochemical changes on 
cell surfaces8,9,10. In the presence of cells, FPs are rapidly displaced from the AuNP surface 
and fluorescence restored. Fluorescence "turn on" of the FPs depends on the drug-induced 
cell surface changes, generating patterns that identify specific mechanisms of cell death 
induced by drugs. The nanosensor is generalisable to different cell types and does not 
require processing steps prior to analysis, offering an effective way to expedite research in 
drug discovery, toxicology and cell-based sensing.
Rapid determination of the mechanism of drug candidates would greatly facilitate the 
discovery and optimisation of new therapeutics11, particularly in the emerging area of 
personalised medicine12. Recently, “signature”-based profiling of drug mechanisms has 
provided a powerful strategy in drug discovery1,2, 13, 14, 15, 16. These screening methods 
measure a series of molecular/phenotypic changes of cells/multicellular organisms induced 
by chemotherapeutic agents and create a fingerprint that is used as a reference for 
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uncharacterized compounds. Several signature-based drug screening studies using traditional 
intracellular biomarkers1–7 require multi-step processing of cells such as extracting 
biomarker1,2,4,5 or labeling cells6,14 and specialised equipment, limiting adoption of these 
strategies in rapid drug screening.
Cell surface phenotypes have been utilised in sensing cell states using nanoparticle-based 
array sensors17,18. These sensors follow a hypothesis-free signature-based 
strategy14,16,19,20,21,22 that allows them to be “trained” to identify diverse bioanalytes. 
However, the single channel output of these nanosensors required separate measurements for 
each array element, and were unable to differentiate between subtle cell surface phenotypic 
differences arising from different cell death mechanisms. We introduce a new multiplexed 
three-channel sensor platform created through supramolecular assembly/disassembly of a 
functionalised AuNP with three FPs. The simultaneous triple-channel fluorescence 
transduction provides a ratiometric output that enhances the accuracy of measurements. 
Moreover, the information-rich output allows determination of chemotherapeutic mechanism 
from a single measurement that provides answers far faster (minutes) than current methods, 
and using standard laboratory instrumentation.
The sensor was generated by non-covalent conjugation of a benzyl headgroup-terminated 
AuNP (BenzNP, Fig. 1a) with three FPs (EBFP2, EGFP and tdTomato). The FPs serve dual 
roles of exhibiting differential supramolecular affinities with the particle, and transducing 
the binding events. BenzNPs were used in the sensor based on our previous studies that 
indicated its effectiveness in profiling cell surface phenotypes17. In these BenzNP-FP 
supramolecular complexes, the cationic AuNP binds strongly with the anionic FPs, resulting 
in quenching of the FP fluorescence by the particle core. The binding equilibria between 
BenzNP and the FPs are altered in presence of cells due to competitive binding to cell 
surfaces, resulting in rapid (seconds/minutes) displacement of FPs from the particle surface 
with consequent restoration of FP fluorescence (Fig. 1b). The fluorescence "turn-on" of the 
three emission channels differs considerably depending on the signatures of drug-treated cell 
surfaces.
A key issue in the sensor design is selecting appropriate FPs from the broad range of 
variants23 such that they provide reproducible sensor responses. Through tests with different 
FP variants we selected a three colour FP set for the present study: blue (EBFP2), green 
(EGFP), and red (tdTomato). This optimised set of proteins was selected to: (i) bear net 
negative charge and feature minimum spectral ‘crosstalk’ with well-separated excitation and 
emission spectra, obtaining independent responses from each channel, (ii) exist as 
monomers or tandem dimers, simplifying their use in displacement assays relative to other 
multimeric analogs, (iii) be photostable, providing reliable outputs.
A second requirement for the FP transducer is differential and reversible interaction with 
BenzNP recognition element. We determined the binding parameters by fluorescence 
quenching studies that provided the complex stability constant and association stoichiometry 
for each FP (Supplementary Fig. 4). It was observed that the binding affinities of BenzNP 
and FPs varied over three orders of magnitude (Fig. 1c), providing the differential affinity 
required for multi-channel output.
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We demonstrated the ability of the BenzNP-FP sensor platform to categorise 
chemotherapeutic mechanisms using a set of apoptosis- and necrosis-inducing chemical 
agents with established mechanisms (Supplementary Table 3, 4). These clinical and 
experimental drugs cover common mechanisms of therapeutic action in cancer and include 
several groups with a common target (macromolecule/pathway). The necrotic agents induce 
cell death by rapid plasma membrane rupture24, which would be expected to generate a 
strong surface response. Apoptotic drugs cause programmed cell death that is associated 
with alterations of the plasma membrane including translocation of molecules from the 
cytosol, as well as suppression of signaling macromolecules8,9,10,24. We tested the 
hypothesis that these drug-induced cell surface alterations could be rapidly discerned using 
the nanosensor. We used BT549 human breast cancer cells (triple negative) as a testbed for 
profiling chemotherapeutic mechanisms, since chemotherapy serves as the only systemic 
therapy for patients with this type of cancer25.
Drug screening studies followed the straightforward protocol shown in Fig. 2. Cell culture, 
drug treatment, and the sensing studies were carried out in a single well of a 96-well 
microplate. For consistency, the cells were treated with drugs at their half-maximal 
inhibitory concentrations (IC50) (Supplementary Fig. 5, Table 3). We confirmed that the 
number of cells attached to the plate for each drug was consistent, ensuring that sensor 
differentiation arose from difference in cell surfaces. Notably, the sensor itself did not 
exhibit any cytotoxicity (Supplementary Fig. 7) and cellular uptake of the particle is 
negligible within the short experimental time26, making our sensing strategy non-interfering 
in terms of cell behaviour.
Initially, we used 15 chemotherapeutics that act through different molecular mechanisms 
(Fig. 3a) to generate a reference set based on fluorescence responses. Upon interaction with 
the drug-treated cells, the sensor generated characteristic fluorescence fingerprints for the 
three FPs (see Supplementary Information for discussion on the role of each fluorescence 
channel). The distinct responses along each FP channel arise from the differential non-
covalent interactions such as electrostatic and π–π stacking with the different biomolecules 
expressed on the drug-treated cell surfaces. Hierarchical clustering analysis (HCA) of the 
fluorescence responses produced seven distinct clusters (Fig. 3a), each corresponding to an 
individual molecular mechanism. The differential response pattern in the heat plot 
demonstrates the sensitivity of the sensor to drug-induced cell surface changes.
The multidimensional sensor data was quantitatively interpreted using linear discriminant 
analysis (LDA). LDA classified the 15 drugs into seven distinct clusters according to the 
different pathways/targets of the drugs (Fig. 3b). Notably, drugs with similar molecular 
mechanisms showed overlapping clusters that were quantifiably distinguishable from other 
mechanistic categories. The distinctly separate region between the apoptotic and necrotic 
groups demonstrates the ability of the sensor to demarcate between broader classes of cell 
death mechanisms. It should be noted that the group size may determine the broadness of 
each drug category, with some categories amenable to further subdivisions27. We validated 
the robustness of the LDA method by leave-one-out cross-validation using a Jackknifed 
analysis. The between-group (mechanism) cross-validation accuracy was 99% 
(Supplementary Table 6), indicating the trained classifier to be a reliable and robust 
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statistical tool. The generality of our strategy was assessed using another cell line with 
entirely different genotype/phenotype, viz. pTD cells (murine mammary cancer cells) that 
provide an important testbed for exploring therapeutics to regulate oncogenic epithelial-
mesenchymal transition28. Characteristic fluorescence responses from the drug-treated pTD 
cells were generated and yielded distinct mechanism-based clusters. These clusters were 
somewhat different than that observed with BT549, as expected based on the geno/
phenotypic difference between cell lines (Supplementary Fig. 10).
The ability to identify the mechanism of lead compounds as either known or novel is a key 
issue in drug screening. In blinded experiments we assessed seven anticancer agents that 
exhibit mechanisms similar to the training set. We predicted the mechanism of the test 
compounds by determining the probability of a compound belonging to the closest reference 
group using an appropriate F-distribution for the minimum Mahalanobis distance obtained 
from LDA. Using a cutoff p-value of 0.01, the analysis correctly predicted the molecular 
mechanisms of the seven test compounds (Fig. 3c), demonstrating the capability of the 
sensor to screen 'real' unknowns. We next sought to examine if the sensor can identify 
compounds involving targets/pathways different from the reference set. Seven compounds 
with “novel” (i.e. outside the reference set) cell death mechanisms were tested using the 
nanosensor. Implementing the same probabilistic analysis, p-value for each compound was 
found to be less than 0.01 (Fig. 3c), indicating that the compounds were far from all the 
training groups and could be readily classified as “novel”. Furthermore, a follow-up LDA 
solution space including the reference and novel compound set showed clearly distinct 
clusters, while the drugs with similar targets paired with each other correctly 
(Supplementary Fig. 11), indicating the ability to update the training set with ‘new’ 
mechanistic groups with sufficient resolution. We tested the robustness of prediction by 
studying eight parallel replicates of the blinded unknowns and the novel compounds that 
resulted in 87.5% (98 of 112 samples) correct prediction (Supplementary Fig. 12). The 
capability of the sensor to discriminate between learned and potentially new mechanisms 
demonstrates the ability of the system to avoid false positives in mechanism identification. 
The ability of the sensor to stratify molecularly targeted drugs such as the HDAC and CDK 
inhibitors suggests its applicability to broader class of modern targeted drugs (targeting 
EGFR, HER2, PDGFR, VEGF, proteasome, etc)29 that cause up/downregulation of the 
receptors on cell surfaces.
Combination therapy provides a complementary strategy to new drug discovery, greatly 
enhancing the efficacy of chemotherapeutics, e.g. by overcoming the drug resistance of 
cancer cells30. Drug combinations produce therapeutic activities (synergistic, additive, or 
antagonistic)31 at different ratios of the individual components. Thus, a cell surface-based 
quick screening of the therapeutic activities with respect to individual drug mechanisms 
should lead to predicting the contribution of each drug in their therapeutic combination32,33.
We demonstrated the ability of our sensor to determine mechanistic correlation between 
individual drugs and their combinations using three apoptotic drugs: apigenin (APG), 
puromycin (PUR), and cisplatin (CSP). We utilized fractional inhibitory concentration 
index34 (Supplementary Equation 1) to select the synergistic drug combinations. 
Interestingly, pairwise interactions of the drugs showed synergy or additivity depending on 
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the ratios of the individual drugs (Fig. 4a). Comparison of the APG-CSP synergistic pairs 
with the single-drug components indicated that both the combinations exhibited a DNA 
crosslinking-like mechanism, consistent with previous observations35 of APG enhancing the 
cytotoxicity of CSP. The LDA scores quantified the similarity of the signatures of APG-CSP 
synergistic combinations to CSP with p>0.01 (Fig. 4b, Supplementary Table 9). Similarly, 
the signature of the PUR-CSP(1:3) combinations revealed its close proximity to protein 
synthesis inhibition-like mechanism (Fig. 4c), suggesting CSP potentiating the PUR-induced 
cytotoxicity. However, PUR-CSP(1:1) and the PUR-APG synergistic combinations were 
classified quite far (p<0.01) from their single-drug components (Fig. 4c,d), indicating a 
mechanistically distinct cell surface phenotypic change that provides a potentially new 
therapeutic strategy. These representative examples indicate that the sensor can provide an 
information-rich strategy for predicting the mechanisms of drug combinations.
In summary, we demonstrated the creation of a novel multichannel sensor based on non-
covalent supramolecular complexes. This sensor uses an engineered nanoparticle and three 
different FPs to provide a three-channel sensor that can be “trained” to detect subtle changes 
in cell surface properties. This biocompatible nanosensor can identify specific mechanisms 
induced by different chemotherapeutic agents, using a single well of a microplate, making 
this strategy applicable to massively high-throughput screening. The simplicity and 
effectiveness of the system underscores its potential to accelerate drug discovery, greatly 
facilitating the development of new therapeutics and drug “cocktails”. This sensor system 
also provides a potential way forward for toxicology, providing a viable method to classify 
the tens of thousands of commercial chemicals for which no data are available.
Methods
Fluorescent proteins were expressed in Escherichia coli BL21 (DE3) and purified by means 
of Co2+ affinity chromatography. BenzNP particles (diameter: ~2 nm) were synthesized 
following a previous report17 and characterized by standard methods. The working 
stoichiometry of NP-FP conjugate was determined through fluorescence titration. The 
binding parameters were obtained from nonlinear least-squares curve fitting analysis of the 
fluorescence responses as a function of concentration of the particles. The sensor was then 
prepared by incubating 150 nM BenzNP and an equimolar mixture of EBFP2, EGFP, and 
tdTomato (final concentration of each protein was 100 nM) for 30 min. Before drug 
screening studies, the IC50 concentration for each drug was determined by incubating 
different concentrations of drugs with BT549 and pTD cells for 24 h, followed by an Alamar 
blue assay. Fluorescence intensity of the dye was plotted as a function of percentage viable 
cells and IC50 was calculated through curve-fitting using a dose response model. Cells were 
counted using a hemocytometer to confirm the number of cells after drug treatment to be 
similar for each drug. For the drug screening studies, 10,000 (for BT549) or 15,000 (for 
pTD) cells/well were cultured in 96-well black-and-clear bottom microplates. Drugs were 
incubated with the cells at their IC50 concentrations for 24 h in the respective culture media. 
After washing the cells with phosphate buffered saline, the sensor was incubated with the 
cells for 15 min and the fluorescence intensities were simultaneously recorded along each 
fluorescence channel on a Molecular Device Spectramax M3 plate reader using appropriate 
filters. The fluorescence responses were statistically analyzed using LDA and HCA in Systat 
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and R software. LDA was employed to predict the mechanism of the test compounds by 
computing their Mahalanobis distance to the center of each of the training groups, followed 
by determining the probability of the compound belonging to its closest cluster using as 
appropriate F-distribution for the minimum distance. Detailed description of the methods 
can be found in the Supplementary Information.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Assembly and working principle of the nanosensor
a, Fabrication of the three-channel nanosensor (BenzNP–FPs complex). The sensor was 
prepared by incubating BenzNP to an equimolar mixture of three FPs at a ratio that was 
determined through fluorescence titration (Supplementary Fig. 4). b, Schematic diagram 
illustrating the displacement and fluorescence turn-on of FPs by cell-surface functionalities. 
c, Differential affinity of BenzNP to tdTomato (red), EBFP2 (blue) and EGFP (green) 
protein. The association constant (Ka) was determined through titration of equimolar 
mixture of FPs with BenzNP (Supplementary Table 1).
Rana et al. Page 8
Nat Nanotechnol. Author manuscript; available in PMC 2017 July 12.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2. Workflow for nanosensor-based drug screening
The Schematic diagram illustrates the drug screening workflow. Cells cultured in a 96-well 
microplate are treated with chemotherapeutic drugs at their IC50 concentrations for 24 h 
followed by washing and incubation the nanosensor. Different drug-treated cells result in 
distinct cell surface phenotypes and hence different FP displacement patterns as 
schematically shown for the three wells. The bar plot shows differential fluorescence 
responses for three representative drugs that may corroborate with the schematic of FP 
displacement. The change in fluorescence along three channels was recorded simultaneously 
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(Supplementary Table 11), where I0 and I are the fluorescence intensity before and after the 
addition of the sensor to the cells, respectively. The responses are averages of eight replicate 
data and the error bars represent ±standard deviation.
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Figure 3. Screening of chemotherapeutic drug mechanisms using fluorescence fingerprints
a, Heat map of the fluorescence response patterns for the reference drug set. Hierarchical 
clustering was performed on the log-transformed average of the fluorescence responses 
(Supplementary Table 11) using a correlation metric and average linkage. The resulting 
dendrograms show the degree of association of the drugs, as well as each FP. Literature-
reported mechanisms of each drug (Supplementary Table 3) are listed next to the heat map. 
b, Clustering the reference drugs via LDA of the fluorescence responses. The canonical 
scores were obtained from LDA on the fluorescence responses, and were plotted with 95% 
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confidence ellipses around the centroid of each group. c, Probabilistic predictions of drug 
mechanisms utlising the fluorescence signatures. The p-values were calculated for the 
averages of eight replicates using the shortest Mahalanobis distance to the centroid of the 
nearest cluster in the reference set that was derived from LDA. A p-value of <0.01 was 
considered to be evidence of a “novel” drug mechanism.
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Figure 4. Profiling the mechanisms of drug combinations
a, Determination of therapeutic activities of pairwise drug combinations using fractional 
inhibitory concentration index (FICI)34. The FICI values of different combinations were 
determined using Supplementary Equation (1) that utilised the IC50 concentrations of the 
drug combinations obtained from the Alamar blue assays. b,c,d, Correlation of the 
synergistic combinations of apigenin-cisplatin (b), puromycin-cisplatin (c), and puromycin-
apigenin (d) with the single-drug mechanistic categories. The canonical scores were 
calculated for the pairwise combinations with the mechanistic groups that contain the single-
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drug components forming the combinations. The LDA-derived scores from the fluorescence 
responses were plotted with 95% confidence ellipses around the centroid of each group. The 
mechanistic categories consist of several drugs with the same mechanism (cf. 
Supplementary Fig. 13), viz. Topo II inhibition: daunorubicin, etoposide, doxorubicin, and 
apigenin; DNA crosslinking: cisplatin, chlorambucil, and oxaliplatin; Protein synthesis 
inhibition: anisomycin, emetin, and puromycin. Each drug was used in eight replicates.
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